2027 ICD-10-CM Diagnosis Code D32.9Benign neoplasm of meninges, unspecified
ICD-10-CM Codes›C00–D49›D10-D36›D32
- Billable — Valid for Submission
- Risk Adjusts — HCC 23
- Chronic Condition
D32.9 is a billable ICD-10-CM diagnosis code for benign neoplasm of meninges, unspecified. It is valid on HIPAA claims for fiscal year 2027 (October 1, 2026 through September 30, 2027) and groups to MS-DRG 54 through 55. In AHRQ's Clinical Classifications Software (CCSR), this diagnosis falls under Benign neoplasms.
For Medicare Advantage risk adjustment, D32.9 maps to CMS-HCC Category 23 (Prostate, Breast, and Other Cancers and Tumors) under the V28 model, adding a risk factor of about 0.186 for a community, non-dual, aged beneficiary in payment year 2027.
Code Identity
Code Classification
Medicare Risk Adjustment (HCC)Billing
D32.9 maps to a payment category in the CMS-HCC model used to risk-adjust Medicare Advantage payments. Weights are the published community factors for payment year 2027.
Source: CMS Payment Year 2027 risk adjustment mappings and model software. Weights are relative factors, not dollar amounts; a beneficiary's total RAF also includes demographics and interactions. Browse all CMS-HCC categories.
Approximate SynonymsGuidance
Alternate terms and clinical phrases that map to this code.
- Benign meningioma
- Benign neoplasm of meninges
- Familial multiple benign meningioma
- Malignant meningioma
- Malignant meningioma of optic nerve sheath
- Malignant neoplasm of optic nerve sheath
- Melanocytoma of meninges
- Meningioma of optic nerve sheath
- Metastatic malignant meningioma
- Primary melanocytic lesion of meninges
- Secondary optic nerve sheath meningioma
Instructional NotesGuidance
Instructions from the official ICD-10-CM Tabular List that apply to D32.9: its own notes plus those printed at Chapter 2. A note printed at a category, block or chapter applies to every code under it.
Applicable To
Conditions this code is used for: synonyms of the title or, for "other specified" codes, the conditions assigned to it. The list is not exhaustive.
- Meningioma NOS
Notes
General instructions on how these codes are used.
- Functional activity
- All neoplasms are classified in this chapter, whether they are functionally active or not. An additional code from Chapter 4 may be used, to identify functional activity associated with any neoplasm.
- Morphology [Histology]
- Chapter 2 classifies neoplasms primarily by site (topography), with broad groupings for behavior, malignant, in situ, benign, etc. The Table of Neoplasms should be used to identify the correct topography code. In a few cases, such as for malignant melanoma and certain neuroendocrine tumors, the morphology (histologic type) is included in the category and codes.
- Primary malignant neoplasms overlapping site boundaries
- A primary malignant neoplasm that overlaps two or more contiguous (next to each other) sites should be classified to the subcategory/code .8 ('overlapping lesion'), unless the combination is specifically indexed elsewhere. For multiple neoplasms of the same site that are not contiguous, such as tumors in different quadrants of the same breast, codes for each site should be assigned.
- Malignant neoplasm of ectopic tissue
- Malignant neoplasms of ectopic tissue are to be coded to the site mentioned, e.g., ectopic pancreatic malignant neoplasms are coded to pancreas, unspecified (C25.9).
Source: CMS ICD-10-CM Tabular List. How to read instructional notes.
Referenced in Other NotesGuidance
Instructional notes printed at other codes that name D32.9, its category, or a range that includes it.
Clinical ClassificationClinical
AHRQ’s CCSR groups this code into broader clinical categories.
Clinical InformationClinical
Grade I Meningioma
a slow-growing, low-grade meningioma with favorable prognosis. this category includes angiomatous meningiomas, fibrous meningiomas, lymphoplasmacyte-rich meningiomas, meningothelial meningiomas, metaplastic meningiomas, microcystic meningiomas, psammomatous meningiomas, secretory meningiomas, and transitional meningiomas. it may recur in a small minority of cases following resection.
Table of NeoplasmsClinical
Anatomical sites in the Table of Neoplasms that reference this code family.
Patient EducationClinical
Benign Tumors
Tumors are abnormal growths in your body. They can be either benign or malignant. Benign tumors aren't cancer. Malignant ones are. Benign tumors grow only in one place. They cannot spread or invade other parts of your body. Even so, they can be dangerous if they press on vital organs, such as your brain.
Read the full article at MedlinePlus
Courtesy of MedlinePlus, a service of the U.S. National Library of Medicine.
Convert D32.9 to ICD-9-CMHistory
The closest ICD-9-CM equivalents under the General Equivalence Mappings.
Code HistoryHistory
Questions About D32.9Overview
What is the ICD-10 code for benign neoplasm of meninges, unspecified?
The ICD-10-CM code for benign neoplasm of meninges, unspecified is D32.9 (sometimes written as D329). It is billable on HIPAA-covered claims from October 1, 2026 through September 30, 2027.
Is D32.9 (Benign neoplasm of meninges) a billable code?
Yes. This is a billable ICD-10-CM code, specific enough to report benign neoplasm of meninges, unspecified on HIPAA-covered claims from October 1, 2026 through September 30, 2027.
What MS-DRG does D32.9 group to?
When benign neoplasm of meninges, unspecified is the principal diagnosis on an inpatient stay, it groups to MS-DRG 55, 54, with relative weights from 1.0291 to 1.5197 depending on complications. Higher weights mean higher Medicare reimbursement.
What is the ICD-9 equivalent of D32.9?
Under the General Equivalence Mappings, benign neoplasm of meninges, unspecified converts to ICD-9-CM 225.2 (ben neo cerebr meninges). The mapping is approximate, so confirm the match fits the documentation.
What HCC is D32.9?
D32.9 (benign neoplasm of meninges, unspecified) maps to CMS-HCC Category 23 (Prostate, Breast, and Other Cancers and Tumors), commonly written as HCC 23, in the CMS-HCC V28 model used for Medicare Advantage risk adjustment in payment year 2027. It mapped to HCC 12 under the retired V24 model. It also maps in the PACE (CMS-HCC V22), ESRD (V21), and ESRD (V24) models. In the Part D prescription drug model it maps to RxHCC 22.
Does D32.9 risk-adjust for Medicare Advantage payment?
Yes. When documented and reported on a Medicare Advantage encounter, D32.9 adds a risk adjustment factor of about 0.186 to the beneficiary's RAF score for a community, non-dual, aged enrollee (published V28 weights range from 0.186 to 0.237 depending on the payment segment). A more severe related category (HCC 17, HCC 18, HCC 19, HCC 20, HCC 21, and HCC 22) supersedes it when both are reported. See the full factor table on the HCC 23 category page.
